| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/24/2007 | CA2629461A1 Substituted quinolones and methods of use |
| 05/24/2007 | CA2629455A1 Heteroalkyl linked pyrimidine derivatives |
| 05/24/2007 | CA2629443A1 Oxygen linked pyrimidine derivatives |
| 05/24/2007 | CA2629437A1 Pharmaceutical compositions comprising methotrexate |
| 05/24/2007 | CA2629429A1 Inhibitors of akt activity |
| 05/24/2007 | CA2629347A1 Synergistic combinations of norketamine and opioid analgesics |
| 05/24/2007 | CA2629323A1 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| 05/24/2007 | CA2629314A1 Tec kinase inhibitors |
| 05/24/2007 | CA2629312A1 Compositions and methods for treating cns disorders |
| 05/24/2007 | CA2629245A1 Neuroendocrine tumor treatment using mtor inhibitors |
| 05/24/2007 | CA2629232A1 Azaindole-2-carboxamide derivatives |
| 05/24/2007 | CA2629162A1 Serum response factor and myocardin control alzheimer cerebral amyloid angiopathy |
| 05/24/2007 | CA2629080A1 Novel pyrrolidine derivatives as inhibitors of coagulation factor xa |
| 05/24/2007 | CA2629031A1 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments |
| 05/24/2007 | CA2628996A1 Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 05/24/2007 | CA2628750A1 4-oxadiazolyl-piperidine compounds and use thereof |
| 05/24/2007 | CA2628666A1 Atorvastatin formulation |
| 05/24/2007 | CA2628650A1 Quinazolines useful as modulators of voltage gated ion channels |
| 05/24/2007 | CA2628630A1 Compositions of lipoxygenase inhibitors |
| 05/24/2007 | CA2628461A1 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| 05/24/2007 | CA2628455A1 Imidazopyrazines as protein kinase inhibitors |
| 05/24/2007 | CA2628332A1 New method for treating cancer based on the modulation of calcineurin |
| 05/24/2007 | CA2628321A1 Treatment of asthma and copd using triple-combination therapy |
| 05/24/2007 | CA2628179A1 Azaindazoles useful as inhibitors of kinases |
| 05/24/2007 | CA2628175A1 Rapamycin derivative or an impdh inhibitor for treating polycystic kidney disease |
| 05/24/2007 | CA2628172A1 Organic compounds comprising a glycopyrronium salt |
| 05/24/2007 | CA2628170A1 Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases |
| 05/24/2007 | CA2628145A1 Novel dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other disorders |
| 05/24/2007 | CA2628047A1 Process for production of cinnamide derivative |
| 05/24/2007 | CA2627982A1 Soft anticholinergic esters |
| 05/24/2007 | CA2627968A1 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements |
| 05/24/2007 | CA2627965A1 Imidazopyrazines as cyclin dependent kinase inhibitors |
| 05/24/2007 | CA2627886A1 Method for treating joint damage |
| 05/24/2007 | CA2627790A1 Compositions useful for prevention and treatment of common cold and influenza-like symptoms |
| 05/24/2007 | CA2627541A1 Oxazole compound and pharmaceutical composition |
| 05/24/2007 | CA2626368A1 Pharmaceutical compositions for the administration of aptamers |
| 05/24/2007 | CA2626122A1 Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| 05/24/2007 | CA2625572A1 Amino acid derivatives |
| 05/24/2007 | CA2589204A1 Recombinant bcg strains with enhanced ability to escape the endosome |
| 05/23/2007 | EP1788092A1 Method of inhibiting postischemic reperfusion-induced cell death and cell death inhibitor |
| 05/23/2007 | EP1788085A1 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 05/23/2007 | EP1788000A1 Agent for preventing and ameliorating obesity |
| 05/23/2007 | EP1787992A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group |
| 05/23/2007 | EP1787991A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE |
| 05/23/2007 | EP1787988A2 Production of furanones |
| 05/23/2007 | EP1787987A1 Substituted fullerenes and their use as antioxidants |
| 05/23/2007 | EP1787986A1 Hydroxamic acid derivative and medicine containing the same as active ingredient |
| 05/23/2007 | EP1787985A1 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom |
| 05/23/2007 | EP1787984A2 Azacyclic compounds for use in the treatment of serotonin related diseases |
| 05/23/2007 | EP1787982A2 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds |
| 05/23/2007 | EP1787980A2 Crystalline and pure modafinil, and process of preparing the same |
| 05/23/2007 | EP1787979A1 Sulfonamide derivative selectively inhibiting mmp-13 |
| 05/23/2007 | EP1787970A1 Method of obtaining polyphenolic extracts from cocoa beans, the extracts obtained and their applications |
| 05/23/2007 | EP1787657A1 Therapeutic agent for psychoneurotic disease |
| 05/23/2007 | EP1787652A1 Composition with antifungal properties, use and method |
| 05/23/2007 | EP1787650A2 A therapeutic composition containing an organosilane quaternary compound and hydrogen peroxide for treating skin disorders |
| 05/23/2007 | EP1787649A1 Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
| 05/23/2007 | EP1787648A1 Medicinal composition for percutaneous perospirone administration |
| 05/23/2007 | EP1787647A1 Remedy for glomerular diseae |
| 05/23/2007 | EP1787646A2 Novel method of treatment |
| 05/23/2007 | EP1787645A1 New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway |
| 05/23/2007 | EP1787644A1 Otological solution and method for its preparation |
| 05/23/2007 | EP1787643A1 Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof |
| 05/23/2007 | EP1787640A1 Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition |
| 05/23/2007 | EP1787639A2 Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 05/23/2007 | EP1787638A1 Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application |
| 05/23/2007 | EP1787637A2 Composition for veterinary use |
| 05/23/2007 | EP1787625A1 Preventive/remedy for obesity |
| 05/23/2007 | EP1787624A1 Skin-lightening agent containing polyphenol compound |
| 05/23/2007 | EP1787532A2 Microbial oil mixtures and uses thereof |
| 05/23/2007 | EP1787529A2 Composition and methods using an eutomer |
| 05/23/2007 | EP1787115A2 Methods of diagnosis of attention deficit hyperactivity disorder (adhd) |
| 05/23/2007 | EP1786907A2 Screening assays for inhibitors of a staphylococcus aureus siderophore |
| 05/23/2007 | EP1786905A1 Small interfering rna molecules against ribonucleotide reductase and uses thereof |
| 05/23/2007 | EP1786823A1 Alkylidene tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents |
| 05/23/2007 | EP1786822A1 Fused tricyclic derivatives for the treatment of psychotic disorders |
| 05/23/2007 | EP1786820A1 9-(1',5'-dimethyl-1'-vinyl-4'-hexenyl)-4-hydroxy-7h-furo[3,2-g][1]benzopyran-7-one as antibacterial agent |
| 05/23/2007 | EP1786819A1 Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments |
| 05/23/2007 | EP1786818A1 Dihydropteridine derivatives, methods for their preparation and their use as drugs |
| 05/23/2007 | EP1786817A1 Pteridinones used as plk (polo like kinases) inhibitors |
| 05/23/2007 | EP1786816A1 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity |
| 05/23/2007 | EP1786815A1 Spiro compounds and methods for the modulation of chemokine receptor activity |
| 05/23/2007 | EP1786814A1 Bicyclononene derivatives as renin inhibitors |
| 05/23/2007 | EP1786812A1 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| 05/23/2007 | EP1786811A2 Triazolopyridine compounds |
| 05/23/2007 | EP1786810A1 Ligands for g-protein coupled receptors |
| 05/23/2007 | EP1786809A2 Aminopiperidine derivatives, preparation thereof and use thereof as melanocortin receptor agonists |
| 05/23/2007 | EP1786807A1 Heterocyclic antiviral compounds |
| 05/23/2007 | EP1786806A1 Dpp-iv inhibitors |
| 05/23/2007 | EP1786805A1 Oxazolidinone compounds and compositions and methods related thereto |
| 05/23/2007 | EP1786804A1 Substituted indole compounds and their use as 5-ht6 receptor modulators |
| 05/23/2007 | EP1786803A1 Pyrimidinylpyrazoles as tgf-beta inhibitors |
| 05/23/2007 | EP1786802A1 Pyrimidinylimidazoles as tgf-beta inhibitors |
| 05/23/2007 | EP1786801A1 Cytokine inhibitors |
| 05/23/2007 | EP1786800A2 Substituted biaryl piperazinyl-pyridine analogues |
| 05/23/2007 | EP1786799A1 Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
| 05/23/2007 | EP1786793A1 Tertiary amine salts of 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid |
| 05/23/2007 | EP1786790A1 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| 05/23/2007 | EP1786788A1 Substituted triazines as prion protein ligands and their use to detect or remove prions |
| 05/23/2007 | EP1786787A1 2,4,6-TRIAMINO-S-TRIAZINE-BASED COMPOUNDS WHICH BIND TO THE TAIL (Fc) PORTION OF IMMUNOGLOBULINS AND THEIR USE |